Patent 9249174 was granted and assigned to Alios BioPharma, Inc. on February, 2016 by the United States Patent and Trademark Office.
Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.